Could a vitamin d pill help stroke survivors think clearly again?
NCT ID NCT07767214
First seen Aug 17, 2026 · Last updated Aug 21, 2026 · Updated 2 times
Summary
This trial tests whether high-dose vitamin D supplements can improve cognitive function in people who have had a stroke and developed thinking or memory problems. Participants will receive either vitamin D or a placebo for six months, and researchers will measure changes in cognitive tests and immune markers in the blood. The goal is to see if vitamin D can reduce inflammation and support brain recovery after a stroke.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Vitamin D2 (ergocalciferol) supplements
- What this could lead to
- If effective, vitamin D could become a simple, safe add-on therapy to help stroke survivors regain cognitive function.
- What could go wrong
- This is an early-stage trial, and results may not show a clear benefit. High-dose vitamin D can have side effects, and the immune effects are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age: Aged 18 to 80 years (inclusive). * Diagnosis: First-ever ischemic or hemorrhagic stroke, confirmed by brain CT or MRI within 1 week of onset. * Time Window: Post-stroke duration between 3 months and 24 months. * Cognitive Status: Presence of cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score \< 26 (or your specific cutoff) at screening. * Stability: Clinically stable condition, without recurrent stroke or transient ischemic attack (TIA) in the past 3 months. * Consent: Ability to provide written informed consent by the participant or their legal representative. * Compliance: Willingness and ability to comply with the study protocol and follow-up visits. Exclusion Criteria: * Severe Disability: Pre-morbid or current modified Rankin Scale (mRS) score \> 3. * Other CNS Diseases: Presence of other neurological diseases that could cause cognitive decline (e.g., Parkinson's disease, epilepsy, brain tumor, or severe traumatic brain injury). * Psychiatric Disorders: History of major psychiatric disorders (e.g., schizophrenia, severe depression) that may interfere with cognitive testing. * Vitamin D Status: Known history of hypercalcemia, hypercalciuria, or sarcoidosis; or current use of vitamin D supplements (\>800 IU/day) or calcium supplements within the past 3 months. * Severe Comorbidities: Severe dysfunction of heart, liver, or kidney (e.g., ALT/AST \> 3x ULN, eGFR \< 30 mL/min/1.73m²). * Life Expectancy: Life expectancy less than 6 months due to malignant tumors or other terminal illnesses. * Allergy: Known allergy or hypersensitivity to vitamin D or any components of the study formulation. * Participation: Participation in another interventional clinical trial within the past 30 days.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Post-stroke cognitive impairment (PSCI) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Suzhou Hospital Affiliated to Anhui Medical University
Suzhou, Anhui, 234000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.